Drug intelligence / Profile preview

ILV-095

Development stage: Discontinued
Lead developer: Pfizer
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

ILV-095 is a monoclonal antibody developed as an interleukin-22 (IL-22) inhibitor for the treatment of psoriasis. It was initially developed by Wyeth and later by Pfizer. The drug acts by targeting and inhibiting IL-22, a cytokine implicated in the pathogenesis of psoriasis through its role in keratinocyte proliferation and skin inflammation. Despite its novel mechanism aimed at modulating immune responses in autoimmune skin diseases, clinical development was discontinued after phase 1 trials due to lack of efficacy or other strategic reasons[1][2][3][4][7][8].

Targets

IL22 (Interleukin 22)

Beyond the preview

Go deeper on ILV-095.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ILV-095.

Explore the full profile